69383-41-1

Upstream product

• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 1679-18-1 4-Chlorophenylboronic acid 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 106-48-9 4-chloro-phenol 
• 148401-42-7 [4-(4-chloro-phenoxy)-phenyl]-acetic acid 

Downstream Products

• 63349-50-8 methyl α-bromo-α-[p-(p-chlorophenoxy)phenyl]acetate 
• 1415596-12-1 C₃₂H₂₈ClNO₂S 
• 1415596-14-3 C₂₅H₂₂ClNO₂S 
• 1415596-30-3 C₃₂H₃₇ClN₂O₂S 
• 1415596-28-9 C₃₃H₃₇ClN₂O₂S 
• 1415596-69-8 C₁₆H₁₆ClNO₃ 
• 1415596-70-1 C₁₈H₁₉ClO₂ 
• 1415596-71-2 C₁₈H₁₈Cl₂O₂ 
• 148401-42-7 [4-(4-chloro-phenoxy)-phenyl]-acetic acid 
• 174522-59-9 4-(4-chloro-phenoxy)phenylacetyl chloride 

Relevant academic research and scientific papers

Synthesis and structure activity relationships of cyanopyridone based anti-tuberculosis agents

Mycobacterium tuberculosis, the causative agent of tuberculosis, relies on thymidylate kinase (MtbTMPK) for the synthesis of thymidine triphosphates and thus also DNA synthesis. Therefore, this enzyme constitutes a potential Achilles heel of the pathogen. Based on a previously reported MtbTMPK 6-aryl-substituted pyridone inhibitor and guided by two co-crystal structures of MtbTMPK with pyridone- and thymine-based inhibitors, we report the synthesis of a series of aryl-shifted cyanopyridone analogues. These compounds generally lacked significant MtbTMPK inhibitory potency, but some analogues did exhibit promising antitubercular activity. Analogue 11i demonstrated a 10-fold increased antitubercular activity (MIC H37Rv, 1.2 μM) compared to literature compound 5. Many analogues with whole-cell antimycobacterial activity were devoid of significant cytotoxicity.

Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer's disease

A series of thiazole derivatives were designed, and prepared to develop RAGE antagonist for the treatment of Alzheimer's disease (AD). SAR studies were performed to optimize inhibitory activity on Aβ-RAGE binding. SAR studies showed that introducing an amino group at part A was essential for inhibitory activity on Aβ-RAGE binding. Compounds selected from Aβ-RAGE binding screening displayed inhibitory activity on Aβ transport across BBB. They also showed inhibitory activity against Aβ-induced NF-κB activation. These results indicated that our derivatives had a potential as therapeutic agent for the treatment of AD.

Barbituric acid derivatives

Derivatives of 5,5-disubstituted pyrimidine-2,4,6-trianones are disclosed. These compounds have antitumor and antimetastatic activity.

Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds

Compounds of formula I in which R1represents a substituted or unsubstituted phenoxy, phenylthio, phenylsulfinyl, phenylsulfonyl, phenylamino or phenylmethyl residue, and R2represents an optionally substituted aryl or heteroaryl resid